MapLight Therapeutics Ownership | Who Owns MapLight Therapeutics?
MapLight Therapeutics Ownership Summary
MapLight Therapeutics is owned by 58.29% institutional investors, 53.14% insiders. Novo is the largest institutional shareholder, holding 8.14% of MPLT shares. T. Rowe Price Small-Cap Stock is the top mutual fund, with 1.38% of its assets in MapLight Therapeutics shares.
MPLT Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | MapLight Therapeutics | 58.29% | 53.14% | -11.44% |
| Sector | Healthcare Stocks | 247.07% | 12.15% | -159.22% |
| Industry | Biotech Stocks | 385.89% | 11.79% | -297.68% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Novo | 3.69M | 8.14% | $132.13M |
| Fcpm iii services b.v. | 3.23M | 7.13% | $115.63M |
| T. rowe price investment management | 2.78M | 6.14% | $99.70M |
| Nan fung group | 2.30M | 5.06% | $23.44M |
| Goldman sachs group | 1.95M | 4.30% | $69.83M |
| Blackrock funding, inc. /de | 1.71M | 3.77% | $17.45M |
| Fmr | 1.54M | 3.39% | $15.71M |
| Price t rowe associates inc /md/ | 1.42M | 3.14% | $51.00M |
| Vanguard group | 869.67K | 2.10% | $15.28M |
| 5am venture management | 950.01K | 2.10% | $34.05M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Nan fung group | 2.30M | 15.66% | $23.44M |
| Fcpm iii services b.v. | 3.23M | 15.41% | $115.63M |
| 5am venture management | 950.01K | 11.83% | $34.05M |
| Velan capital investment management lp | 492.89K | 10.76% | $17.67M |
| Novo | 3.69M | 7.67% | $132.13M |
| Superstring capital management lp | 125.43K | 2.84% | $4.50M |
| Pivotal bioventure partners investment advisor | 611.45K | 2.47% | $6.23M |
| Sanofi | 912.04K | 1.48% | $9.29M |
| Dafna capital management | 171.01K | 1.17% | $6.13M |
| Blue owl capital lp | 556.37K | 1.04% | $5.67M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Nan fung group | 2.30M | 15.66% | 1.33M |
| Price t rowe associates inc /md/ | 1.42M | 0.01% | 1.31M |
| Vanguard group | 869.67K | 0.00% | 869.67K |
| Fmr | 1.54M | 0.00% | 718.38K |
| Blackrock funding, inc. /de | 1.71M | 0.00% | 687.60K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Perceptive advisors | - | - | -550.00K |
| State street | 313.59K | 0.00% | -538.56K |
| Siren | - | - | -450.00K |
| Vestal point capital, lp | - | - | -420.00K |
| Vanguard capital management | 396.08K | 0.00% | -388.07K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vanguard group | 869.67K | 0.00% | 869.67K | $15.28M |
| Paradigm biocapital advisors lp | 685.85K | 0.46% | 685.85K | $24.58M |
| Boxer capital management | 75.00K | 0.20% | 75.00K | $2.69M |
| Quadrature capital | 74.48K | 0.00% | 74.48K | $759.00K |
| Trexquant investment lp | 63.79K | 0.01% | 63.79K | $2.29M |
Sold Out
| Holder | Change |
|---|---|
| Larson financial group | -1.00 |
| True wealth design | -3.00 |
| Mai capital management | -12.00 |
| Covestor | -16.00 |
| Sjs investment consulting | -18.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 109 | 34.57% | 26,392,574 | 6.85% | 58 | 1.96% | 62 | 29.17% | 28 | 115.38% |
| Mar 31, 2026 | 28 | -62.16% | 2,594,337 | -88.75% | 5 | 0.19% | 16 | -78.38% | 5 | - |
| Dec 31, 2025 | 33 | - | 8,880,682 | - | 21 | - | 33 | - | - | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price Small-Cap Stock | 625.05K | 1.38% | -233.00 |
| T. Rowe Price US Small-Cap Core Equity | 625.05K | 1.38% | -678.00 |
| Vanguard Total Stock Mkt Idx Inv | 552.28K | 1.22% | 73.70K |
| Vanguard Morn Total Stk Mkt Idx Investor | 552.28K | 1.22% | 73.70K |
| State Street® SPDR® S&P® Biotech ETF | 490.72K | 1.08% | 1.13K |
| T. Rowe Price U.S. SC Value Eq Tr-D | 411.66K | 0.91% | -2.40K |
| T. Rowe Price Integrated US SmCapGrEq | 402.79K | 0.89% | 402.79K |
| T. Rowe Price Small-Cap Value | 493.26K | 0.89% | - |
| T. Rowe Price New Horizons | 398.81K | 0.88% | 195.20K |
| US Small-Cap Growth II Equity Comp | 398.81K | 0.88% | 332.41K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Oct 15, 2026 | Kreitzer Anatol | Chief Discovery Officer | Sell | $96.02K |
| Oct 15, 2026 | GILLIS JONATHAN | CAO and Interim CFO | Sell | $82.15K |
| Oct 15, 2026 | Lillie James Woodruff | Chief Scientific Officer | Sell | $93.03K |
| Oct 15, 2026 | Hanson Kristopher | General Counsel | Sell | $72.88K |
| Oct 15, 2026 | Foff Erin Pennock | Chief Medical Officer | Sell | $124.07K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q4 | - | 6 |
| 2026 Q3 | 7 | 46 |
| 2026 Q2 | - | - |
MPLT Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools